KTTA · NASDAQ

Pasithea Therapeutics (KTTA) Stock Price & Fundamentals

$872.30+0.03%+$0.23End-of-day price as of Oct 9, 2026

Sample prices

Prices on this page are generated sample data for development, not real market data, so market cap, P/E and dividend yield are illustrative too. Fundamentals are real, from Pasithea Therapeutics's SEC filings.

Pasithea Therapeutics (KTTA) closed at $872.30 on Oct 9, 2026, up 0.03% from the previous close of $872.07.

Share price, past year

1Y +9.50%

52-week range $688.74 – $929.05. Daily closing prices.

Monthly closing prices

Last closing price of each month
Date	Close
Oct 9, 2026	$872.30
Sep 30, 2026	$846.74
Aug 31, 2026	$918.09
Jul 31, 2026	$870.79
Jun 30, 2026	$852.91
May 29, 2026	$846.14
Apr 30, 2026	$798.75
Mar 31, 2026	$772.39
Feb 27, 2026	$731.79
Jan 30, 2026	$711.57
Dec 31, 2025	$742.75
Nov 28, 2025	$735.89
Oct 31, 2025	$782.06

Key statistics

Market cap: $29.15B
P/E (TTM): —
EPS (TTM): −$0.92
Revenue (TTM): —
Net income (TTM): −$21.29M
Shares outstanding: 33.4M
Dividend yield: —
52-week range: $688.74 – $929.05

Pasithea Therapeutics's market cap is $29.15B, based on a share price of $872.30 and 33.4M shares outstanding as of Jun 30, 2026.

Financials

Pasithea Therapeutics reported revenue of $486.56K for fiscal 2022, up 3,130.37% from fiscal 2021.

Pasithea Therapeutics reported a net loss of $20.43M in fiscal 2025.

Annual revenue

FY21FY22

Pasithea Therapeutics annual financials by fiscal year, from SEC filings
Fiscal year	Revenue	Growth	Net income	Net margin	EPS (diluted)	Free cash flow
FY2022ended Dec 31, 2022	$486.56K	+3,130.4%	−$13.94M	−2,864.3%	−$1.76	−$14.67M
FY2021ended Dec 31, 2021	$15.06K	—	−$2.17M	−14,430.5%	−$0.21	−$3.20M

Pasithea Therapeutics quarterly results
Quarter	Revenue	Net income	EPS (diluted)
Q4 FY2022ended Dec 31, 2022	$240.71K	—	—
Q3 FY2022ended Sep 30, 2022	$218.61K	—	—
Q2 FY2022ended Jun 30, 2022	$13.58K	—	—
Q1 FY2022ended Mar 31, 2022	$13.66K	—	—

Company profile

Name: Pasithea Therapeutics Corp.
Ticker: KTTA
Exchange: NASDAQ
Industry (SEC SIC): Pharmaceutical Preparations
Headquarters: 1111 Lincoln Road, Suite 500, Miami Beach, FL 33139
Incorporated in: DE
Fiscal year ends: December
SEC CIK: 0001841330

Recent SEC filings

8-KCurrent report for period ending Sep 16, 2026
Sep 16, 2026
8-KCurrent report for period ending Sep 9, 2026
Sep 9, 2026
8-KCurrent report for period ending Aug 20, 2026
Aug 21, 2026
10-QQuarterly report for period ending Jun 30, 2026
Aug 14, 2026
10-QQuarterly report for period ending Mar 31, 2026
May 15, 2026
8-KCurrent report for period ending May 1, 2026
May 4, 2026
10-KAnnual report for period ending Dec 31, 2025
Mar 30, 2026
8-KCurrent report for period ending Feb 20, 2026
Feb 20, 2026

Frequently asked questions

What is Pasithea Therapeutics's stock price?

Pasithea Therapeutics (KTTA) closed at $872.30 on Oct 9, 2026, up 0.03% from the previous close of $872.07.

What is Pasithea Therapeutics's market cap?

Pasithea Therapeutics's market cap is $29.15B, based on a share price of $872.30 and 33.4M shares outstanding as of Jun 30, 2026.

How much revenue does Pasithea Therapeutics make?

Pasithea Therapeutics reported revenue of $486.56K for fiscal 2022, up 3,130.37% from fiscal 2021.

Does Pasithea Therapeutics pay a dividend?

Pasithea Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Pasithea Therapeutics Corp.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures